It's going to take a few years to get there.
News & Analysis: Momenta Pharmaceuticals
MNTA earnings call for the period ending March 31, 2019.
The biotech is waiting for proof-of-concept data expected next year.
MNTA earnings call for the period ending December 31, 2018.
Volatility strikes the biotech.
Investors are excited about all the capital the biotech raised.
The biotech is shifting focus away from biosimilars and toward its pipeline of immune drugs.
MNTA earnings call for the period ending September 30, 2018.
The company's plan to restructure itself isn't sparking investor optimism.
Find out how earnings hurt some of these stocks.